id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-P-0102-0063,FDA,FDA-2000-P-0102,"Petition Response Letter from FDA CDER to Anthony L. Young on behalf of Botanical Laboratories, Inc.",Other,Letter(s),2020-05-26T04:00:00Z,2020,5,2020-05-26T04:00:00Z,,2020-05-26T18:15:54Z,,0,0,09000064846aeba0
FDA-2000-P-0102-0065,FDA,FDA-2000-P-0102,Petition Response Letter from FDA CDER to Mr Raubicheck  on behalf of Pharmachem Laboratories Inc.,Other,Letter(s),2020-05-26T04:00:00Z,2020,5,2020-05-26T04:00:00Z,,2020-05-26T18:33:32Z,,0,0,09000064846af68d
FDA-2000-P-0102-0062,FDA,FDA-2000-P-0102,Petition Response Letter from FDA CDER to Anthony L. Young on behalf of Pharmavite,Other,Letter(s),2020-05-26T04:00:00Z,2020,5,2020-05-26T04:00:00Z,,2020-05-26T18:08:59Z,,0,0,09000064846aef27
FDA-2000-P-0102-0064,FDA,FDA-2000-P-0102,Petition Response Letter from FDA CDER to Ms. Guggenheim on behalf of Cargill,Other,Letter(s),2020-05-26T04:00:00Z,2020,5,2020-05-26T04:00:00Z,,2020-05-26T18:20:39Z,,0,0,09000064846aebf8